Korean Chinese Japanese
  • Economy
  • Politics
  • Society
  • Securities
  • Real estate
  • Culture
  • Entertainment
  • Sports
  • Opinion
Korean Chinese Japanese
Economy Corporation Pharma & Bio
Society Politics IT·Science
Securities Real Estate Global
Opinion Entertainment Sports Culture
Video Auto in Golf in
PHARM EDAILY Market in TheBeLT
IT·Science
Internet

Even When AI Handles Payments, Final Approval Requires a Text Message… Why SKT Is Pushing for Text Message Standardization

Text messaging from telecommunications carriers, which had once lost its prominence due to competition from KakaoTalk, is finding a new role in the era of Agent AI. As we enter an era where AI orders …
  • 2026-09-15 12:55:30
  • Kim Hyun-ah
Technology

QuantaMatrix Incorporated Changes Its Brand Name to “Qumico”… Expanding Synergies with MiCo Ltd. Through Entry into New Businesses

QuantaMatrix Incorporated(317690)is making a fresh start as “QMiCo.” This is part of the company’s first business restructuring since MiCo Ltd.’s large-scale investment last year. The company plans to…
  • 2026-09-15 12:01:02
  • Minji Son
Mobile

"Breaking the 150-Year-Old Telecommunications Mold"... SamsungElectronics Successfully Detects Crowds in Real Time Using 6G

(Photo courtesy of SamsungElectronics) SamsungElectronics(005930)has unveiled technology that uses 6G communication networks to detect the movements of large crowds in real time without the need f…
  • 2026-09-15 11:56:07
  • Han Kwangbeom
Mobile

iPhone Dominates Its Home Market… Galaxy Foldable Phones Really Made Their Mark

SamsungElectronics(005930) The “Galaxy Z8” series ranked among the top in a foldable smartphone evaluation by a U.S. consumer magazine.According to the mobile industry on the 15th, SamsungElectronics’…
  • 2026-09-15 11:08:42
  • Shin Yeong-bin
Technology

Celltrion Launches U.S. Phase 4 Trial of High-Dose Zymfentra

Celltrion is launching a Phase 4 clinical trial in the United States to establish clinical evidence supporting a 240 mg high-dose regimen of its autoimmune disease treatment Zymfentra, also known as i…
  • 2026-09-15 10:45:03
  • NA EUN-KYUNG
Technology

Celltrion Begins U.S. Phase 4 Clinical Trial for High-Dose (240 mg) ‘Zimpentra’

Celltrion(068270)Celltrion is launching a U.S. Phase 4 clinical trial to establish the safety and efficacy of a 240 mg high-dose regimen of “Zimpendra” (active ingredient: infliximab), a treatment for…
  • 2026-09-15 10:37:02
  • NA EUN-KYUNG
Technology

Genomictree Inc. Develops LNP Technology to Deliver mRNA to the Brain and Spinal Cord

Genomictree Inc.(228760)has developed a lipid nanoparticle (LNP) technology that delivers messenger RNA (mRNA) to the brain and spinal cord via intravenous injection without the need for a separate ta…
  • 2026-09-15 10:24:02
  • NA EUN-KYUNG
Technology

Graphy Inc. Launches 3D Printing Material for Dental Prosthetics That “Prints Without Trimming”

#Graphy Inc. has launched “Tera Harz E-Namel” (R-191), a 3D-printing-based aesthetic prosthetic material, and is expanding its dental prosthetics business.Graphy Inc. announced on the 15th that it had…
  • 2026-09-15 10:13:02
  • NA EUN-KYUNG
Internet

KakaoTalk Launches New "Lifestyle" Tab for Koreans in North America… Kicks Off Expansion of Global Advertising

Kakao(035720)has launched a new “Local News” tab on KakaoTalk in North America that aggregates lifestyle information for Koreans living there. The plan is to expand KakaoTalk’s global utility by impro…
  • 2026-09-15 09:13:40
  • Lee So-Hyun
Internet

SOCAR Launches ‘Instant Delivery’ Service Throughout Seoul… Cars Delivered Within an Hour

SOCAR(403550)is launching its “Instant Delivery” service, which delivers a vehicle to any desired location within one hour after a request is made anywhere in Seoul. This strategy aims to expand the u…
  • 2026-09-15 08:49:32
  • Lee So-Hyun
prev 21 22 23 24 25 26 27 28 29 30 next

PHARM EDAILY

Shorts

EDAILY
  • 92, Tongil-ro, Jung-gu, Seoul, Korea
  • +82 2 3772 0114
  • webmaster@edaily.co.kr

※ This article has been translated using AI technology for the convenience of readers.

EDAILY provides this translation on an “as is” basis and makes no warranties, express or implied, regarding its accuracy, reliability, completeness, merchantability, or fitness for a particular purpose.
Due to the limitations of machine translation, the translated content may differ from the original Korean article. In the event of any discrepancy, the original Korean version shall prevail.
EDAILY shall not be liable for any loss or damage arising from the use of, or reliance on, the translated content.

© 2026 Copyrights by edaily. All Rights Reserved.
Korea China Japan
English